Llwytho...
Cardiac Myosin Activation for the Treatment of Systolic Heart Failure
Left ventricular systolic dysfunction is the hallmark pathology in heart failure with reduced ejection fraction. Increasing left ventricular contractility with beta-adrenergic receptor agonists, phosphodiesterase-3 inhibitors, or levosimendan has failed to improve clinical outcomes and, in some situ...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | J Cardiovasc Pharmacol |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7779665/ https://ncbi.nlm.nih.gov/pubmed/33165138 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FJC.0000000000000929 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|